Description
Dapagliflozin is an SGLT2 inhibitor.
Dapagliflozin
Product ID D019601
Cas No. 461432-26-8
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 461432-26-8 |
|---|---|
| Purity | ≥98% |
| Formula | C21H25ClO6 |
| Formula Wt. | 408.88 |
| Synonym | BMS-512148 |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Ogutveren M, Satiroglu O, Ozden Z, et al. Cardioprotective effects of dapagliflozin and trimetazidine on doxorubicin-induced cardiotoxicity in streptozocin-induced type 1 diabetic rats via endoplasmic reticulum stress. J Clin Med. 2025 Feb 16;14(4):1315. PMID: 40004844.
Xiong S, Huang L, Liu H, et al. Dapagliflozin exerts anti-apoptotic effects by mitigating macrophage polarization via modulation of the phosphoinositide 3-kinase/protein kinase B sigmaling pathway. World J Diabetes. 2025 Feb 15;16(2):97287. PMID: 39959262.
Londzin P, Zych M, Janas A, et al. Effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin and canagliflozin, on the musculoskeletal system in an experimental model of diabetes induced by high-fat diet and streptozocin in rats. Biomed Pharmacother. 2025 Mar:184:117912. PMID: 39955854.
Hirose T, Takagi H, Kuno M, et al. Dapagliflozin increased pancreatic beta cell proliferation and insulinogenic index in mice fed a high-fat and high-sodium chloride diet. Biochem Biophys Res Commun. 2025 Feb 16:749:151364. PMID: 39855047.
Liu Y, Bai H, Guan H, et al. Animal experiments and network pharmacology to explore the anti-inflammatory mechanism of dapagliflozin in the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2025 Dec;41(1):2454432. PMID: 39826530.